Table 2 Demographic and clinical characteristics of the study population
Number (percentage) | ||
|---|---|---|
Age (years) | Range | 18–58 |
Median | 34 | |
Gender | Male | 29 (27.6%) |
Female | 76 (72.4%) | |
Type of MS | RRMS | 95 (90.5%) |
SPMS | 9 (8.5%) | |
PPMS | 1 (1.0%) | |
Total duration of illness (months) | Range | 1–25 |
Median | 5 | |
EDSS score | Range | 0–7 |
Median | 2.5 | |
EDSS grading | Mild disability (0–3) | 69 (65.7%) |
Moderate disability (3.5–6) | 28 (26.7%) | |
Severe disability (˃6) | 8 (7.6%) | |
Number of relapses during the last year | No relapse | 40 (38.1%) |
One relapse | 49 (46.7%) | |
Two relapses | 13 (12.4%) | |
More than two relapses | 3 (2.8%) | |
DMT | Interferon beta | 49 (46.7%) |
Dimethyl fumarate | 1 (1.0%) | |
Teriflunomide | 5 (4.7%) | |
Fingolimod | 39 (37.1%) | |
Rituximab | 10 (9.5%) | |
Ocrelizumab | 1 (1.0%) | |
Hauser Ambulation index | Range | 0–9 |
Median | 1 | |